90% of families. 6, 7 Over 3000 different likely causative DNA variants have been reported to date in the F8 and F9 genes. [8] [9] [10] [11] [12] The discovery of F8 inversion variants in introns 1 and 22 that disrupt the F8 structural gene explained the cause of haemophilia in almost onehalf of patients with severe haemophilia A 13, 14 and increased knowledge of structural variation in genetic disease, in general.
| The impact of F8 and F9 genotypes on haemophilia outcomes
F8 and F9 genetic information is used in reproductive planning, including in pregnancy and neonatal management. 15 The knowledge of genetic carrier status of the mother and specifics of the genotype related to haemophilia disease severity can guide evaluation of the mother's personal bleeding risks and plans for treatment, as needed, as well as inform potential risks in the foetus and neonate. While the optimal mode of delivery for a foetus with severe haemophilia is debated, a Caesarean delivery may be the safest approach for many haemophilic infants. 16 Regardless of mode of delivery, knowledge of foetal status can guide management decisions during labour and delivery, including avoidance of procedures and instrumentation that can cause neonatal trauma, such as forceps or vacuum-assisted extraction in vaginal and Caesarean deliveries. 15, 16 The potential for non-invasive testing of maternal blood for diagnosis of haemophilia in the foetus should make prenatal diagnosis more common in the future. 17, 18 In addition, immediate medical evaluation of the neonate and treatment, if needed, is possible when the haemophilia diagnosis is known at birth.
Additionally, specific kinds of F8 and F9 genotypes are associated with increasing the patient's risk of developing a neutralizing antibody (inhibitor) against infused exogenous factor replacement therapy. [19] [20] [21] [22] In haemophilia B, inhibitor formation occurs in 3%-5%
of patients with severe disease (<1% FIX activity), and the risk is increased further in those with partial or whole gene deletions. 21 Patients who develop inhibitors are at risk of a severe allergic reaction at the time of onset of the inhibitor. 22, 23 For this reason, genetic analysis soon after diagnosis is important in clinical management of severe haemophilia B.
The presence of deleterious variants in F8 significantly impacts the risk for inhibitor formation in haemophilia A. 19, 20 About 25%-30% of patients with severe haemophilia A develop inhibitors within approximately 14 exposure days, 24, 25 which usually occurs in young children, given treatment patterns. Inhibitor risk is reported to be higher in population groups, including in African Americans, for reasons that have yet to be determined. 21 Inhibitor risk is lower in patients with mild and moderate disease (FVIII activity 1%-40%) than in patients with severe disease, but inhibitors still develop with an incidence reported at 6.7% at 50 exposure days. 20 Inhibitor risk in mild and moderate haemophilia A is increased by prolonged factor exposure and is influenced by genetic variation in the F8 gene. 20, 26 In patients with severe haemophilia A, the incidence of inhibitors is greatest in patients with disruptive structural variation such as large multi-exon deletions (67%-88%) and comparatively less in those with haemophilia due to missense variants (<12% 
| E XPAND ING K NOWLEDG E IN HAEMOPHILIA AND ITS OUTCOME S THROUG H OMI C S
Some haemophilia-causing DNA variants are located outside the usual targets for haemophilia DNA sequencing diagnostics, likely affecting regulatory regions beyond the coding sequences usually tested, such as variants positioned deep within introns. [41] [42] [43] In addition, our understanding of clinically relevant haemophilia phenotypes, including variations in bleeding severity and risk of inhibitor development, likely involves genetic and epigenetic variation outside the F8 and F9 genes.
Advances in technology and our understanding of the human genome now allow more comprehensive methods to study genomic variation. 44 Linking DNA variants, be they single nucleotide variants (SNVs) or structural variants such as copy number variants (CNVs), to protein structure and human phenotypes has greatly advanced our understanding of disease over the past decade. 45 In addition, studies of the transcriptome and proteome are key to advancing our understanding of disease states and their associated clinical outcomes. 46 For example, the immune transcriptome should perceptibly change in patients as they are exposed to factor concentrate during the time in which they develop an inhibitor and again in response to immune tolerance, if instituted. 47 When genomic data are paired with standardized phenotypic data, such approaches are powerful tools for scientific discovery and precision medicine.
The Trans-Omics in Precision Medicine (TOPMed) programme of the National Heart, Lung, and Blood Institute (NHLBI) of the U.S.
National Institutes of Health (NIH) has as its goal to use genomic
and other-omic data to improve diagnosis and care for patients with heart, lung, blood, and sleep disorders and advance precision medicine. The MyLifeOurFuture (MLOF) project is a nationwide U.S. initiative which provides genotyping for patients and families affected by haemophilia and supports a research repository. The MLOF research cohort is part of the TOPMed programme, poised to leverage-omics resources to advance our understanding of haemophilia and its treatment. 
| THE MY LIFE OUR FUTURE
for DNA capture, 48,49 targeting all F8 and F9 exons, splice sites, promoter and untranslated DNA regions, and 5′ and 3′ of
| MLOF interim results
The 
| Defining pathogenicity for variants in F8 and F9
Outside of the region encoding the FVIII B domain, the F8 and F9 genes had previously purported to be highly conserved with little benign variation in the coding regions, and thus, it was common clinical practice to assume that DNA variants detected in either the F8 or F9 gene are the cause of the patient's haemophilia A or haemophilia B, respectively. This assumption has been questioned for F8, 53 and a study of F8 genetic variation in the 1000 Genomes Project supports the presence of considerable benign variation in the F8 gene across ethnic groups. 54 Interrogation of the ExAC database for F8 and F9
variants captured in whole exome sequencing of ~66,000 individuals further supports that there is considerable rare variation in both genes. 55 In the MLOF project, knowledge of the subjects' haemophilia A or haemophilia B status and simultaneous sequencing of both the 
| MLOF AND OMIC S THROUG H THE NHLB I TOPMED PROG R AMME
While a major purpose of MLOF was to genotype the F8 and F9 genes, participants were offered the opportunity to contribute their samples to a research repository for future study. Overall, 81% of participants elected to enrol in the research repository, which collected DNA, RNA, plasma and serum protein samples and provides links to clinical data in ATHN. These data and samples are available to interested investigators through an application and review process.
The NHLBI TOPMed programme is using high throughput-omics technologies to characterize molecular abnormalities or signatures associated with heart, lung, blood and sleep disorders, to conduct analyses of data generated by this programme and to build and share tools for advanced data analysis. Through this resource, DNA from 5141 MLOF subjects has undergone whole genome sequencing Characterizing SV using NGS approaches remains a challenge.
Study of the haemophilia WGS data, particularly of the F8 genomic region given the frequency of SV associated with haemophilia A, will advance our knowledge and applications in this area. A focused preliminary analysis of the first 2181 genomes has allowed us to explore using a WGS approach to analyse the F8 and F9 genomic regions for SV. We find that small and large SVs can be detected, including variants that are likely causal for severe haemophilia (factor levels <1%)
as they are predicted to disrupt gene structure. Moreover, the identification of SVs which impact both a haemophilia gene and neigh- 
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